Nasdaq8 months ago
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $25.00 at Robert W. Baird
Karyopharm Therapeutics Stock Target Cut to $25 by Robert W. Baird In a dramatic shift, Karyopharm Therapeutics (NASDAQ: KPTI), a biotech company focused on novel cancer...
